Cheelcare Inc (CHER) investor relations material

Executive summary

• Achieved significant progress in U.S. commercialization of Companion following Medicare and Medicaid reimbursement eligibility, with expanded dealer and clinician engagement.

• Secured a Canadian patent for the Companion platform, strengthening North American intellectual property protection.

• Advanced engineering and regulatory milestones for Curio, including completion of cybersecurity testing and ongoing FDA 510(k) process.

Financial highlights

• Revenue reached $828,516, up 98% year-over-year from $417,981 in Q1 fiscal 2026.

• Gross profit was $481,637 with a gross margin of 58.1%, compared to $212,787 and 50.9% in the prior year.

• Net loss narrowed to $501,008 ($0.02 per share) from $1,630,108 ($0.15 per share) in Q1 fiscal 2026, which included a significant listing expense.

• Cash and cash equivalents stood at $2.4 million as of July 31, 2026, up from $163,416 at April 30, 2026.

Outlook and guidance

• Focus remains on leveraging expanded reimbursement access and distribution to drive sustained Companion growth.

• Plans to improve manufacturing efficiency as volumes increase and to advance Curio through further engineering, validation, and regulatory work.